果冻影院

XClose

果冻影院 Queen Square Institute of Neurology

Home
Menu

Information for Researchers

To learn more about the study and the study team, please click on the relevant section below.

About the study

There are many听disease modifying treatments (DMTs) for patients with Multiple Sclerosis (MS).听 Currently, there is no clinical tool to help patients select the medication that will work best for them and the decision is often made according to factors such as drug administration, frequency of drug administration and risk of side effects.听 If patients continue to suffer from relapses or have serious side effects, they can听switch听to another DMT.听 The consequences of this policy that requires a听DMT to 鈥渇ail鈥 before prescribing another one听include听continuous relapses, accumulation of disability and unnecessary side effects.

We aim to collect all manifestations of MS that may influence individual treatment response and translate machine learning techniques into clinical practice in order to generate a tool which will predict treatment response, thereby guiding the choice of DMT and reducing the risk of adverse events given by unnecessary treatments.

Study Schedule

This is an observational study, where patients with MS initiating a DMT in the NHS will undergo clinical and MRI assessments and blood tests.听 We will recruit adult patients听and children with MS from the MS clinics at 果冻影院H and the UK Paediatric Neuroinflammation Services (Great Ormond Street Hospital, Evelina Children鈥檚 Hospital London and听Birmingham Women & Children鈥檚 Hospital).

Participants will be seen at three timepoints: baseline, 6 months and 18 months.听 At each visit they will undergo a standardised clinical assessment, blood tests for neurofilaments levels, safety data and MRI scans.听听


Clinical Assessment

The clinical assessment will comprise scales for physical disability, such as the EDSS, and听the Brief International Cognitive Assessment for MS (BICAMS).听 Participants will also be asked to complete some patient reported outcome measures (PROMs),听as well as providing information on their medical history, demographics, comorbidities, diet,听education and employment.

Magnetic Resonance Imaging (MRI)

MRI will include standard-of-care protocols, which include听3D-FLAIR and T2-TSE axial imaging and research sequences such as听a volumetric brain sequence (3D-T1).

Genetics

Genetic factors may enable us to identify patients who are at higher risk of accumulation of brain pathology.

The genetic testing will identify those variants previously associated with MS susceptibility and will be undertaken at the 果冻影院 Institute of Neurology by Professor Henry Houlden, Professor of Neurogenetics, and his team.听

Neurofilaments in Serum

Neurofilament levels in serum act as a blood biomarker of axonal damage, allowing for reliable, clinical monitoring of axonal damage in MS patients.听 They will be measured at each time point.

The concentration of neurofilaments in serum will be determined at the 果冻影院 Institute of Neurology by Professor Henrik Zetterberg, Professor of Neurochemistry, and his team, with the neurofilament-light assay.听

Machine Learning

Machine learning will be employed to segment MS lesions.听 Additionally, high-dimensional models will be constructed to predict individual treatment response, using all the characteristics that define the disease in an individual.听

A positive treatment response will be defined as no evidence of disease activity or NEDA (no relapses, no progression of disability and no MRI activity.听 All predictions will be probabilistic.听 The听high-dimensional models will be constructed in a tiered approach and听the most parsimonious, efficient, predictive model will be created.听 Overfitting will be minimised and model training, validation and testing using external datasets will be performed.听

pitms_machine_learning
PITMS Research Team & Partners

果冻影院 and 果冻影院H

Professor Olga Ciccarelli, Principal Investigator

Dr Yael Hacohen, Co-Investigator

Professor Parashkev Nachev, Co-Investigator

Professor Daniel Alexander, Co-Investigator

Professor Henry Houlden, Co-Investigator

Professor Henrik Zetterberg, Co-Investigator

Dr Sarmad Al-Araji, Clinical Research Fellow (2019 - 2022)

Dr Alessia Bianchi, Clinical Research Fellow

Alvin Zapata, Research Nurse

Dr Le Zhang, Research Associate 鈥 Computational Imaging听(2019 - 2022)

Dr Baris Kanber, Senior Research Fellow 鈥 Machine Learning

Amber Strang, Study Coordinator

Great Ormond Street Hospital

, Site Principal Investigator

Dr Omar Abdel-Mannan, Clinical Research Fellow

Katie Hanson, Clinical Nurse Specialist

Evelina Children鈥檚 Hospital

, Site Principal Investigator

Birmingham Women鈥檚 & Children鈥檚 Hospital

, Site Principal Investigator

Publications

Abdel-Mannan O, and the UK-Childhood Inflammatory Disease Network. Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Neurol Neuroimmunol Neuroinflamm. 2021 May 21;8(4):e1008. doi: 10.1212/NXI.0000000000001008.

Al-Araji S, Bianchi A, Eshaghi A, et al, 鈥iccarelli O. Assessing predictors of NEDA in RRMS patients initiating dimethyl fumarate in a real-world setting. P113. Association of British Neurologists (ABN) 2022.

Al-Araji S, Jha A, Zhang L, et al, 鈥iccarelli O. Bayesian prediction of individualised treatment response in multiple sclerosis. ECTRIMS October 2022. Selected for poster award.

Moccia M, Al-Araji, Zhang L, et al鈥, Ciccarelli O. Comparing clinical and radiological effectiveness of disease modifying treatments in the real-world. O955. ECTRIMS October 2022.

Eshaghi A, Young AL, Wijeratne PA, et al鈥, Ciccarelli O. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat Commun. 2021 Apr 6;12(1):2078. doi: 10.1038/s41467-021-22265-2. (*)

Eshaghi A, Wijeratne P, Oxtoby N, et al鈥, Ciccarelli O. Predicting personalized risk of disability worsening in multiple sclerosis with machine learning. Nat Commun. 2022. Major revisions requested. (*)

Zhang L, Tanno R, Bronik K, et al. Ciccarelli O, Alexander DC. "Learning to segment when experts disagree." International Conference on Medical Image Computing and Computer-Assisted Intervention, pp. 179-190. Springer, Cham, 2020.

Zhang L, Tanno, R Xu MG, Ciccarelli O, Barkhof F, Alexander DC. "Disentangling Human Error from the Ground Truth in Segmentation of Medical Images." 34th Conference on Neural Information Processing Systems (NeurIPS 2020).

Contact Us

uclh.pitms@nhs.net

(07976) 846695